tc-510
·Code: TC-510
tc-510: sourced relationships with 1 company · 1 clinical trial tracked.
tc-510 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect tc-510 to TCRR; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could tc-510 → TCRR affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| TCR2 THERAPEUTICS INC. (TCRR) | Phase 1/Phase 2 |
Clinical Trial Registry Records (1)
A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Primary endpoint: Phase 1 - Establish the recommended Phase 2 dose (RP2D) according to dose-limiting toxicity (DLT) of defined adverse events.
Interventionalopen6 targetStarted 2022-06Completion 2028-107 sites · United StatesTCR2 Therapeutics
Frequently asked questions
Which companies have sourced relationships with tc-510?
tc-510 has dated SEC/FDA relationship records for TCR2 THERAPEUTICS INC..
How many clinical trials involve tc-510?
BioSniper tracks 1 clinical trial involving tc-510.